ArticleTrials2025
[
Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06480721 (FET-PET-Guided Management of Pseudoprogression in Glioblastoma), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FET-PET-Guided Management of Pseudoprogression in Glioblastoma
Who cites it
3 citing papers in PubMed.
- Functional outcome after repeat surgery of tumor progression or treatment-associated changes in high-grade glioma: Clinical and radiological predictors.Neuro-oncology practice · 2026Article
- Patient perspectives on diagnostic uncertainty and novel diagnostic tests in neuro-oncology.Neuro-oncology practice · 2026Article
- Utility of dynamicNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundDuring follow-up of glioblastoma patients after chemoradiation, expert teams often observe abnormalities on MRI with difficulty in distinguishing between tumor growth and pseudoprogression. Although advanced MRI techniques such as perfusion weighted imaging provide additional information, diagnostic uncertainty often remains, leading to incorrect or delayed diagnosis, and inappropriate treatment, such as unnecessary surgery. [
methodsA multicenter diagnostic randomized clinical trial will be performed, from August 2024 until December 2027. Adult patients (n=144) with isocitrate dehydrogenase (IDH)-wildtype glioblastoma will be included, who, at least ≥3 months after the concomitant phase of standard temozolomide-based chemoradiation, have new or increased contrast enhancement on MRI, causing doubt between tumor growth or pseudoprogression. In this trial, pseudoprogression will be used as an encompassing term that includes radionecrosis and other treatment-related changes after (chemo-)radiotherapy. Included patients will be randomized 1:1 in two arms. The investigational arm receives an additional [ DISCUSSION: We hypothesize that the clinical management guided by an additional [
trial registrationThe trial is registered on ClinicalTrials.gov on the 24th of June 2024, with registration number NCT06480721.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.